CH451179A - Process for the production of new ketones of the lysergic acid series - Google Patents
Process for the production of new ketones of the lysergic acid seriesInfo
- Publication number
- CH451179A CH451179A CH1471064A CH1471064A CH451179A CH 451179 A CH451179 A CH 451179A CH 1471064 A CH1471064 A CH 1471064A CH 1471064 A CH1471064 A CH 1471064A CH 451179 A CH451179 A CH 451179A
- Authority
- CH
- Switzerland
- Prior art keywords
- general formula
- acid series
- carbon atoms
- lysergic acid
- production
- Prior art date
Links
- ZAGRKAFMISFKIO-QMTHXVAHSA-N lysergic acid Chemical class C1=CC(C2=C[C@H](CN([C@@H]2C2)C)C(O)=O)=C3C2=CNC3=C1 ZAGRKAFMISFKIO-QMTHXVAHSA-N 0.000 title claims description 7
- 238000000034 method Methods 0.000 title claims description 7
- 150000002576 ketones Chemical class 0.000 title claims description 6
- 238000004519 manufacturing process Methods 0.000 title description 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical group [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 3
- 229910052744 lithium Inorganic materials 0.000 claims description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 239000000460 chlorine Substances 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 2
- 125000002950 monocyclic group Chemical group 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 150000002902 organometallic compounds Chemical class 0.000 claims description 2
- 150000003254 radicals Chemical class 0.000 claims description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 1
- 150000002431 hydrogen Chemical group 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- -1 halogenated magnesium radical Chemical class 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical group O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229960004903 invert sugar Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- CEQFOVLGLXCDCX-WUKNDPDISA-N methyl red Chemical compound C1=CC(N(C)C)=CC=C1\N=N\C1=CC=CC=C1C(O)=O CEQFOVLGLXCDCX-WUKNDPDISA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- ANRQGKOBLBYXFM-UHFFFAOYSA-M phenylmagnesium bromide Chemical compound Br[Mg]C1=CC=CC=C1 ANRQGKOBLBYXFM-UHFFFAOYSA-M 0.000 description 1
- 229940072033 potash Drugs 0.000 description 1
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008433 psychological processes and functions Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
- C07D457/02—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with hydrocarbon or substituted hydrocarbon radicals, attached in position 8
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Description
Verfahren zur Herstellung neuer Ketone der Lysergsäurereihe
Es wurde gefunden, dass man zu neuen Ketonen der Lysergsäurereihe der allgemeinen Formel I (siehe Formelblatt), worin Rt Wasserstoff, eine Alkylgruppe mit 1-5 Kohlenstoffatomen oder eine Aralkylgruppe mit 7-9 Kohlenstoffatomen und R2 eine gegebenenfalls durch Alkyl- oder Alkoxygruppen substituierte monocyclische Arylgruppe bedeuten und xy für die Gruppierung
EMI1.1
steht, gelangen kann, indem man Verbindungen der allgemeinen Formel II, worin R1 und xy obige Bedeutung besitzen und ;
R3 und R4 Wasserstoff, oder eine Alkylgruppe mit 1-5 Kohlenstoffatomen bedeuten, oder mit dem Stickstoffatom zusammen eine Pyrrolidin-, PiperidXin-oder Morphoiinring bilden, mit metallorganischen Verbindungen der allgemeinen Formel III, worin R2 obige Bedeutung hat und Me Lithium oder einen Halogenmagnesiumrest, worin Halogen für Chlor, Brom oder Jod steht, bedeutet, umsetzt und den erhaltenen Komplex hydrolysiert.
Als Verbindungen der allgemeinen Formel III eigmel III, worin R2 obige Bedeutung hat und Me Lithium oder einen Halogenmagnesiumrest, worin Haloz. B. Phenyl-magnesium-bromid.
Die Ausführung des Verfahrens gestaltet sich beispielsweise wie folgt: Man versetzt die Lösung eines Lysergsäure-Derivates der allgemeinen Formel II in einem inerten organischen Lösungsmittel, wie z. B.
Benzol oder Äther, mit einer Lösung einer Verbindung der allgemeinen Formel III im gleichen oder in einem verschiedenen organischen Lösungsmittel (z. B. Äther oder Tetrahydrofuran) und lässt die Mischung eine Zeit lang bei Raumtemperatur stehen. Anschliessend wird mit Wasser zersetzt und die organische Schicht abgetrennt. Nach Trocknung der organischen Phase mit Natriumsulfat oder Pottasche wird das Lösungsmittel abgedampft und der Rückstand nach bekannten Methoden durch Kristallisation undltoder Chromatographie an Aluminiumoxyd gereinigt. Die nach dem vorliegenden Verfahren hergestellten neuen Ketone der Lysergsäure-Reihe sind bei Zimmertemperatur meist leicht kristallisierende Substanzen und bilden mit anor ganischen oder organischen Säuren Salze.
Mit dem Keller' schen Farbreagens (Eisen-(III)chlorid enthaltender Eisessig und konz. Schwefelsäure) geben sie eine von der Art des Substituenten Rt abhängige charakteristische Färbung.
Die erfindungsgemäss erhaltenen neuen Ketone der Lysergsäure-Reihe wirken sedativ auf motorische und psychische Funktionen und beeinflussen den Tonus der Gefässe.
Die Erfindung umfasst auch die Herstellung von Salzen der neuen Verbindungen. Solche Salze sind z. B. diejenigen mit anorganischen Säuren, wie Chlorwasserstoffsäure, Bromwasserstoffsäure oder Schwefelsäure, oder mit organischen Säuren, wie Fumarsäure, Maleinsäure, Weinsäure, Methansulfonsäure etc.
Die neuen Verbindungen können als Arzneimittel allein oder in entsprechenden Arzneiformen für enterale oder parenterale Verabreichung verwendet werden. Zwecks Herstellung geeigneter Arzneiformen werden diese mit anorganischen oder organischen, pharmakologisch indifferenten Hilfsstoffen verarbeitet. Als Hiifsstoffe werden verwendet z. B. für Tabletten und Dragees: Milchzucker, Stärke, Talk,
Stearinsäure usw. für Sirupe : Rohrzucker-, Invertzucker-,
Glucoselösungen u. a. für Injektionspräparate: Wasser, Alkohole, Glycerin, pflanzliche Öle und dergl. für Suppositorien : Natürliche oder gehärtete Öle und Wachse u. a. mehr.
Zudem können die Zubereitungen geeignete Konservierungs-, Stabilisierungs-, Netzmittel, Lösungsvermittler, Süss- und Farbstoffe, Aromantien usw. enthalten.
Im nachfolgenden Beispiel, das die Ausführung des Verfahrens erläutert, den Umfang der Erfindung aber in keiner Weise einschränken soll, erfolgen alle Temperaturangaben in Celsiusgraden. Die Schmelzpunkte sind unkorrigiert.
EMI2.1
Beispiel
6-Methyl-8-benzoyl-ergolin Eine Lösung von 0,2 g 9, 1O-DihydroI-lysergsäure- piperidid in 50 ccm siedendem Benzol wird mit 2 ccm einer frisch bereiteten ätherischen Li-phenyl-Lösung, von der 1 com 2,9 ccm 0,2 n HCI auf Methylrot verbraucht, versetzt, wobei sich eine weisse gallertige Fällung ausscheidet. Nach 1 1/2 Stunden Stehen bei Raumtemperatur schüttelt man zwischen Natronlauge und Chloroform aus. Die organische Phase wird über Natriumsulfat getrocknet, das Lösungsmittel abgedampft und der Rückstand an einer Säule von 20g Aluminiumoxyd chromatographiert, wobei das 6-Methyl-8-benzoyl-ergolin mit absolutem Chloroform ins Filtrat gewaschen wird.
Aus Aceton kristallisiert das 6-Methyl-8-benzoyl-ergolin in schiffchenförmigen Blättchen vom Smp. 220-2210 aus. [a] D20 = 1200 (c = 0,5 in Pyridin).
Keller'sche Farbreaktion: violettstichig blau.
Process for the production of new ketones of the lysergic acid series
It has been found that new ketones of the lysergic acid series of the general formula I (see formula sheet), in which Rt is hydrogen, an alkyl group with 1-5 carbon atoms or an aralkyl group with 7-9 carbon atoms and R2 is a monocyclic optionally substituted by alkyl or alkoxy groups Mean aryl group and xy for the grouping
EMI1.1
can be obtained by adding compounds of the general formula II in which R1 and xy have the above meanings and;
R3 and R4 denote hydrogen, or an alkyl group with 1-5 carbon atoms, or together with the nitrogen atom form a pyrrolidine, piperidxine or morphine ring, with organometallic compounds of the general formula III, in which R2 has the above meaning and Me is lithium or a halogenomagnesium radical, wherein halogen represents chlorine, bromine or iodine, means, reacts and hydrolyzes the complex obtained.
As compounds of the general formula III Eigmel III, in which R2 has the above meaning and Me is lithium or a halogenated magnesium radical, in which Haloz. B. phenyl magnesium bromide.
The method is carried out, for example, as follows: The solution of a lysergic acid derivative of the general formula II in an inert organic solvent, such as. B.
Benzene or ether, with a solution of a compound of the general formula III in the same or in a different organic solvent (e.g. ether or tetrahydrofuran) and the mixture is left to stand for a while at room temperature. It is then decomposed with water and the organic layer is separated off. After drying the organic phase with sodium sulfate or potash, the solvent is evaporated off and the residue is purified by known methods by crystallization and chromatography on aluminum oxide. The new ketones of the lysergic acid series produced by the present process are usually easily crystallizing substances at room temperature and form salts with inorganic or organic acids.
With Keller's color reagent (glacial acetic acid containing iron (III) chloride and conc. Sulfuric acid) they give a characteristic color depending on the type of substituent Rt.
The new ketones of the lysergic acid series obtained according to the invention have a sedative effect on motor and psychological functions and influence the tone of the vessels.
The invention also includes the preparation of salts of the new compounds. Such salts are e.g. B. those with inorganic acids such as hydrochloric acid, hydrobromic acid or sulfuric acid, or with organic acids such as fumaric acid, maleic acid, tartaric acid, methanesulfonic acid etc.
The new compounds can be used as medicaments alone or in corresponding medicament forms for enteral or parenteral administration. In order to produce suitable dosage forms, these are processed with inorganic or organic, pharmacologically indifferent auxiliaries. As auxiliary substances are used, for. B. for tablets and dragees: lactose, starch, talc,
Stearic acid etc. for syrups: cane sugar, invert sugar,
Glucose solutions and the like a. for injection preparations: water, alcohols, glycerine, vegetable oils and the like. for suppositories: natural or hardened oils and waxes etc. a. more.
In addition, the preparations can contain suitable preservatives, stabilizers, wetting agents, solubilizers, sweeteners, colorants, flavorings, etc.
In the following example, which explains the implementation of the method but is not intended to limit the scope of the invention in any way, all temperatures are given in degrees Celsius. The melting points are uncorrected.
EMI2.1
example
6-methyl-8-benzoyl-ergoline A solution of 0.2 g of 9, 1O-dihydroI-lysergic acid piperidide in 50 ccm of boiling benzene is mixed with 2 cc of a freshly prepared ethereal Li-phenyl solution, of which 1 com 2, 9 ccm of 0.2 N HCl consumed on methyl red, added, a white gelatinous precipitate separating out. After standing for 1 1/2 hours at room temperature, it is shaken out between sodium hydroxide solution and chloroform. The organic phase is dried over sodium sulfate, the solvent is evaporated off and the residue is chromatographed on a column of 20 g of aluminum oxide, the 6-methyl-8-benzoyl-ergoline being washed into the filtrate with absolute chloroform.
The 6-methyl-8-benzoylergoline crystallizes from acetone in boat-shaped leaves with a melting point of 220-2210. [a] D20 = 1200 (c = 0.5 in pyridine).
Keller's color reaction: violet-tinged blue.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH1471064A CH451179A (en) | 1964-11-13 | 1964-11-13 | Process for the production of new ketones of the lysergic acid series |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH1471064A CH451179A (en) | 1964-11-13 | 1964-11-13 | Process for the production of new ketones of the lysergic acid series |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH451179A true CH451179A (en) | 1968-05-15 |
Family
ID=4403188
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH1471064A CH451179A (en) | 1964-11-13 | 1964-11-13 | Process for the production of new ketones of the lysergic acid series |
Country Status (1)
| Country | Link |
|---|---|
| CH (1) | CH451179A (en) |
-
1964
- 1964-11-13 CH CH1471064A patent/CH451179A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE1695753A1 (en) | Improvements in the preparation of 4-oxopiperidine compounds and certain new 4-oxopiperidine compounds | |
| CH472407A (en) | Process for the preparation of new 2-benzyl-1,3,4,9b-tetrahydro-2H-indeno (1,2-c) pyridine derivatives | |
| DE1493181A1 (en) | Process for the preparation of 5 beta-bisnorcholane derivatives | |
| DE1620286B1 (en) | Process for the preparation of pyrrole derivatives | |
| CH451179A (en) | Process for the production of new ketones of the lysergic acid series | |
| DE1768943B2 (en) | PROCESS FOR PREPARING A COBALT CHELATE COMPLEX | |
| CH616142A5 (en) | ||
| CH493521A (en) | (A) Compds. (I):- where R1 = H or Me; R2 = 7-9 C aralkyl or aryl (opt. substd. by one or more methyl or 1-4 C alkoxy groups, Br or Cl); X Y = CH | |
| AT208870B (en) | Process for the production of new N-substituted azepines or dihydroazepines | |
| AT256114B (en) | Process for the preparation of new benzodiazepine derivatives | |
| DE1114815B (en) | Process for the production of ferrocene derivatives | |
| AT269368B (en) | Process for the preparation of new heterocyclic compounds | |
| AT265273B (en) | Process for the production of new 2-oxo-7-phenyl-1,2,3,4,6,7-hexahydro-11bH-benzo [a] -quinolizines and of their acid addition and quaternary ammonium salts | |
| CH452538A (en) | Process for the preparation of new heterocyclic esters | |
| AT273985B (en) | Process for the preparation of new azabicycloaliphatic compounds and their salts | |
| AT243268B (en) | Process for the preparation of new benzoquinolizine derivatives | |
| AT252924B (en) | Process for the preparation of new benzodiazepine derivatives | |
| AT218526B (en) | Process for the production of new phenthiazine derivatives | |
| AT228409B (en) | Process for the production of new lysergic acids | |
| AT241463B (en) | Process for the preparation of new dibenzocycloheptane derivatives | |
| AT251765B (en) | Process for the production of new yohimban derivatives and their salts | |
| AT276383B (en) | Process for the preparation of new phenylisoindole derivatives and their salts | |
| AT229293B (en) | Process for the preparation of new phenylpropylamine derivatives and their salts | |
| DE1695623B2 (en) | METHOD FOR PRODUCING RACEMIC OR OPTICALLY ACTIVE 6H, 7H - CIS-7 AMINODESACETYLCEPHALOSPORANIC ACID DERIVATIVES | |
| AT303025B (en) | PROCESS FOR THE PRODUCTION OF NEW INDOLDER DERIVATIVES AND THEIR ACID ADDITION SALTS |